The short version of phase 2 trial fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
== Tetramers in immunology == In immunology, MHC tetramers can be used in tetramer assays, to quantify numbers of antigen-specific T cells (especially CD8+ T cells). MHC tetramers are based on recombinant class I molecules that, through the action of bacterial BirA, have been biotinylated. These molecules are folded with the peptide of interest and β2M and tetramerized by a fluorescently labeled streptavidin. (Streptavidin binds to four biotins per molecule.) This tetramer reagent will specifically label T cells that express T cell receptors that are specific for a given peptide-MHC complex. For example, a Kb/FAPGNYPAL tetramer will specifically bind to Sendai virus specific cytotoxic T cell in a C57BL/6 mouse. Antigen specific responses can be measured as CD8+, tetramer+ T cells as a fraction of all CD8+ lymphocytes. The reason for using a tetramer, as opposed to a single labeled MHC class I molecule is that the tetrahedral tetramers can bind to three TCRs at once, allowing specific binding in spite of the low (1 micromolar) affinity of the typical class I-peptide-TCR interaction. MHC class II tetramers can also be made, although these are more difficult to work with practically.
Sculptra is a proprietary formulation of poly-L-lactic acid (PLLA) that is an FDA-approved dermal filler manufactured by Dermik Laboratories, which conducts the American business of Aventis Dermatology, the global dermatology unit of Aventis (of Sanofi-Aventis). PLLA was approved by the FDA on August 3, 2004, for the treatment of facial fat loss (also called facial lipoatrophy). According to documents from the US Food and Drug Administration, the FDA initially approved the drug on the basis of small studies conducted on HIV patients, specifically "for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV). Facial lipoatrophy is a condition in which people lose fat in their faces, especially in their cheeks and around their eyes and temples. People with HIV who take anti-HIV drugs may develop HIV-associated lipodystrophy. Sculptra was subsequently approved by the FDA for use with non-HIV patients with wrinkles, despite substantial complications reported to the FDA. After the injection, it will take around 1 to 1.5 months to grow natural collagen. Bruising and swelling may occur post injection, which will go down within a week. After the injection, patients are directed to massage the treatment area in order to maintain smooth, level and evenly distributed results and prevent granuloma formation.
== Impact on victims == Corrective rape and other accompanying acts of violence can result in physical and psychological trauma, mutilation, unwanted pregnancy, and may contribute to suicide. Corrective rape is a major contributor to HIV infection in South African lesbians. In South Africa, approximately 10% of lesbians are HIV positive, with corrective rape being the most likely cause. HIV in South Africa is an epidemic, and due to homophobia, there is a lack of education about sexually transmitted diseases among lesbians. Homophobic laws and discrimination in South Africa contribute to the poor quality of health care for minorities. The psychological effects of corrective rape on victims can be detrimental. Many victims in countries such as South Africa and India where corrective rape is most prevalent suffer from a strong sense of insecurity and disempowerment due to strong homophobia in their communities. However, violence against the LGBTQ community in South Africa is seldom reported. Many survivors of corrective rape suffer from triple discrimination for being women, Black, and homosexual. This is especially true in South African townships, where corrective rape is common for lesbian women. Corrective rape victims may suffer from depression, anxiety, and/or post-traumatic stress disorder. Due to racial and sexual discrimination in health care, victims must often deal with these issues on their own.
primase Any of a class of enzymes that catalyze the synthesis of short, ~10-base RNA oligonucleotides, which by complementing the lagging strand during DNA replication are used as primers by DNA polymerase to initiate the synthesis of Okazaki fragments.
The wave modes derived from the MHD equations are called magnetohydrodynamic waves, or MHD waves. There are three MHD wave modes that can be derived from the linearized ideal MHD equations for a fluid with a uniform, and constant magnetic field:
Sources: en.wikipedia.org
In a DNA double helix, each type of nucleobase on one strand bonds with just one type of nucleobase on the other strand. This is called complementary base pairing. Purines form hydrogen bonds to pyrimidines, with adenine bonding only to thymine in two hydrogen bonds, and cytosine bonding only to guanine in three hydrogen bonds. This arrangement of two nucleotides binding together across the double helix (from six-carbon ring to six-carbon ring) is called a Watson-Crick base pair. DNA with high GC-content is more stable than DNA with low GC-content. A Hoogsteen base pair (hydrogen bonding the 6-carbon ring to the 5-carbon ring) is a rare variation of base-pairing. As hydrogen bonds are not covalent, they can be broken and rejoined relatively easily. The two strands of DNA in a double helix can thus be pulled apart like a zipper, either by a mechanical force or high temperature. As a result of this base pair complementarity, all the information in the double-stranded sequence of a DNA helix is duplicated on each strand, which is vital in DNA replication. This reversible and specific interaction between complementary base pairs is critical for all the functions of DNA in organisms.
== External links == Electron+Transport+Chain+Complex+Proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Khan Academy, video lecture KEGG pathway: Oxidative phosphorylation, overlaid with genes found in Pseudomonas fluorescens Pf0-1. Click "help" for a how-to.
=== Cryo-EM Facility === The cryo-EM facility at the Life Sciences Institute offers a wide range of advanced microscopes and technologies for cryo-electron microscopy, cryo-electron tomography, and correlative light and electron microscopy (CLEM).
The eastern brown snake (Pseudonaja textilis) has a venom LD50 value of 0.053 mg SC (Brown, 1973) and a value of 0.0365 mg SC (Ernst and Zug et al. 1996). Average venom yield is 2–6 mg (Meier and White, 1995). Average venom yield (dry weight) is between 5–10 mg (Minton, 1974). Maximum venom yield for this species is 155 mg. This species is legendary for its bad temper, aggression, and for its speed. This species is responsible for more deaths every year in Australia than any other group of snakes. Australia reports on average well under 10 snake bite deaths per year due to high levels of snake awareness and education, quality medical facilities and personnel and the availability of anti venom.
Sources: en.wikipedia.org
Ontogeny The development of an individual organism, particularly the growth and differentiation of the nervous system from embryo to adult. Operculum (brain) A part of the cerebral cortex that covers the insula. It includes portions of the frontal, temporal, and parietal lobes. Opsin A light-sensitive protein found in photoreceptor cells of the retina. Plays a key role in the molecular detection of light in vision. Optic chiasm The point at which the optic nerves from both eyes partially cross, allowing visual information from each eye to be processed in both hemispheres of the brain. Optic nerve (Cranial Nerve II) A cranial nerve that transmits visual information from the retina to the lateral geniculate nucleus of the thalamus. Optic tract The continuation of the optic nerve fibers after the optic chiasm; carries visual information to the thalamus and midbrain. Optogenetics A technique that uses light-sensitive proteins to control the activity of genetically targeted neurons. Widely used in neuroscience research to study circuit function. Orbitofrontal cortex A prefrontal brain region involved in decision-making, reward processing, and emotional regulation. Dysfunction is linked to addiction and impulsivity. Organ of Corti The sensory organ within the cochlea that contains hair cells and is responsible for converting sound vibrations into neural signals. Orientation column A vertical column of neurons in the visual cortex that respond to lines of the same orientation. Part of the brain’s system for processing visual features.
Shell cordovan, cordovan, or cordwain is a type of tanned leather. Cordovan is an equine material made from the superficial fascia (or shell) of the lower layers of the hide on the rump of a horse. The material derives its name from the city of Cordoba, Spain, which was long known as a center of leather production and where this type of leather originated. It is a difficult and expensive material to make. Shell cordovan has a unique non-creasing characteristic. Because it is made of connective tissue, it is smooth and lacks the pebbled effect of leather derived from the outer skin.
The above examples envisage nuclear warfare at a strategic level, i.e., total war. However, nuclear powers have the ability to undertake more limited engagements. "Sub-strategic use" includes the use of either "low-yield" tactical nuclear weapons, or of variable yield strategic nuclear weapons in a very limited role, as compared to exchanges of larger-yield strategic nuclear weapons over major population centers. This was described by the UK Parliamentary Defence Select Committee as "the launch of one or a limited number of missiles against an adversary as a means of conveying a political message, warning or demonstration of resolve". It is believed that all current nuclear weapons states possess tactical nuclear weapons, with the exception of the United Kingdom, which decommissioned its tactical warheads in 1998. However, the UK does possess scalable-yield strategic warheads, and this technology tends to blur the difference between "strategic", "sub-strategic", and "tactical" use or weapons. American, French and British nuclear submarines are believed to carry at least some missiles with dial-a-yield warheads for this purpose, potentially allowing a strike as low as one kiloton (or less) against a single target. Only the People's Republic of China and the Republic of India have declarative, unqualified, unconditional "no first use" nuclear weapons policies. India and Pakistan maintain only a credible minimum deterrence.
=== Major neuroendocrine axes === Oxytocin and vasopressin (also called anti-diuretic hormone), the two neurohypophysial hormones of the posterior pituitary gland (the neurohypophysis), are secreted from the nerve endings of magnocellular neurosecretory cells into the systemic circulation. The cell bodies of the oxytocin and vasopressin neurons are in the paraventricular nucleus and supraoptic nucleus of the hypothalamus, respectively, and the electrical activity of these neurons is regulated by afferent synaptic inputs from other brain regions. By contrast, the hormones of the anterior pituitary gland (the adenohypophysis) are secreted from endocrine cells that, in mammals, are not directly innervated, yet the secretion of these hormones (adrenocorticotrophic hormone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, prolactin, and growth hormone) remains under the control of the hypothalamus. The hypothalamus controls the anterior pituitary gland via releasing factors and release-inhibiting factors; these are substances released by hypothalamic neurons into blood vessels at the base of the brain, at the median eminence. These vessels, the hypothalamo-hypophysial portal vessels, carry the hypothalamic factors to the anterior pituitary, where they bind to specific receptors on the surface of the hormone-producing cells. For example, the secretion of growth hormone is controlled by two neuroendocrine systems: the growth hormone-releasing hormone (GHRH) neurons and the somatostatin neurons, which stimulate and inhibit GH secretion, respectively.
=== 5-Hydroxymethylcytosine === Bisulfite sequencing is used widely across mammalian genomes, however complications have arisen with the discovery of a new mammalian DNA modification 5-hydroxymethylcytosine. 5-Hydroxymethylcytosine converts to cytosine-5-methylsulfonate upon bisulfite treatment, which then reads as a C when sequenced. Therefore, bisulfite sequencing cannot discriminate between 5-methylcytosine and 5-hydroxymethylcytosine. This means that the output from bisulfite sequencing can no longer be defined as solely DNA methylation, as it is the composite of 5-methylcytosine and 5-hydroxymethylcytosine.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.